.Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L01E_ProteinKinaseInhibitors.L01EJ04_Momelotinib.Momelotinib .Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L01E_ProteinKinaseInhibitors.L01EJ04_Momelotinib.Momelotinib| name: | Momelotinib | |
| ATC code: | L01EJ04 | route: | oral |
| compartments: | 2 | |
| dosage: | 200 | mg |
| volume of distribution: | 68.2 | L |
| clearance: | 17.6 | L/h |
| other parameters in model implementation | ||
Momelotinib is an orally bioavailable, small molecule inhibitor of Janus kinase 1 and 2 (JAK1/2) and activin A receptor type I (ACVR1). It is primarily used for the treatment of myelofibrosis, a type of myeloproliferative neoplasm, and is approved for this indication.
Pharmacokinetic parameters in adult patients with myelofibrosis following oral administration.